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Abstract
Allergic diseases are among the most common health issues children and adolescents face. Allergic reactions occur 
when the immune system becomes allergically sensitised and are detected by measuring levels of specific 
immunoglobulin E antibodies (IgE antibodies) in the blood. This article discusses the prevalences of bronchial 
asthma, hay fever, atopic dermatitis and allergic contact dermatitis for 0- to 17-year-olds, as well as the prevalence 
of allergic sensitisation to a mix of frequent inhalant allergens (SX1) among 3- to 17-year-olds based on data from 
the second wave of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS 
Wave 2, 2014-2017). 12-month prevalence trends between KiGGS Wave 2 and the KiGGS baseline study (2003-2006) 
are shown according to gender and age group. There were no significant changes in the 12-month prevalence of 
hay fever (8.8%) atopic dermatitis (7.0%) and bronchial asthma (3.5%) compared to the KiGGS baseline study, 
which indicates a stabilisation at a high level. More than one in six children (16.1%) currently suffer from at least 
one of these three diseases. 37.1% of 3- to 17-year-olds are sensitised to the multiple allergen mix SX1. Similar to 
the development of disease prevalence, SX1 sensitisation too has remained stable at a high level over the course 
of the past ten years.
 ALLERGIC DISEASES · ALLERGIC SENSITISATION · CHILDREN · ADOLESCENTS · HEALTH MONITORING
1. Introduction
Allergic diseases such as hay fever (allergic rhinitis), 
bronchial asthma and atopic dermatitis (atopic eczema) 
are among the most common diseases affecting the 
health of children and adolescents. These diseases often 
severely impact the daily lives of those affected. Hay fever 
is an allergic inflammation reaction of the nasal mucosa 
that causes itching, sneezing fits, increased mucus secre-
tion and obstructed nasal breathing. In many cases the 
eyes are affected too. A diverse set of allergens such as 
pollen, moulds, animal epithelial tissue or house dust 
mites can trigger these complaints. Bronchial asthma is 
triggered by an oversensitivity of the bronchia to differ-
ent irritants. This leads to reversible paroxysmal con-
strictions of the bronchial system and may lead to cough-
ing, wheezing when breathing and dyspnoea. In the 
majority of children concerned, allergies are the cause 
of asthma. Atopic dermatitis and allergic contact der-
matitis are different diseases of the skin caused by 
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well as allergic contact dermatitis for children and ado-
lescents aged 0 to 17. For the 3 to 17 age group, the point 
prevalence of allergic sensitisation (at the point of blood 
draw) to a mixture of a respiratory sensitisers (SX1). 
Moreover, differences (trends) in the 12-month preva-
lence of atopic diseases, as well as SX1 sensitisation 
between KiGGS Wave 2 and the KiGGS baseline study 
are presented according to gender and age group.
2.  Methodology
KiGGS is part of the health monitoring system at the 
Robert Koch Institute (RKI) and includes repeated 
cross-sectional surveys of children and adolescents aged 
0 to 17 (KiGGS cross-sectional study) that are represen-
tative for Germany. The KiGGS baseline study (2003-2006) 
was conducted as an examination and interview survey, 
the first follow-up study (KiGGS Wave 1, 2009-2012) as 
a telephone-based interview survey and KiGGS Wave 2 
(2014-2017) as an examination and interview survey. 
Previous articles have provided a detailed description of 
the concept and design of KiGGS [7-10]. In brief, partic-
ipants to be invited were selected randomly from the 
official population registries in 167 cities and municipal-
ities representative for Germany and already used in the 
baseline study. A number of activities have been con-
ducted to increase study participation and to improve 
the sample composition [8, 11]. 15,023 children and ado-
lescents (7,538 girls, 7,485 boys) took part in KiGGS 
Wave 2 (response 40.1%). 3,567 children and adolescents 
(1,801 girls, 1,766 boys) took part in the examinations 
(response 41.5%).
allergy with symptoms such as strong itching, redden-
ing and blistering [1, 2]. 
Allergic sensitisation of the immune system is a pre-
requisite of allergies. Asthma, hay fever and atopic 
dermatitis are caused by specific immunoglobulin E anti-
bodies (IgE antibodies) after an (initial) contact with 
specific, generally harmless substances (allergens), this 
is called atopy. With repeated contact with these same 
allergens, the sensitised immune system remembers 
these allergens and may react with defence mechanisms. 
This can lead to allergic reactions in diverse organs with 
different degrees of severity and symptoms. Allergic 
sensitisation can be measured by analysing specific IgE 
antibodies in the blood. Their detection alone, however, 
is no proof of a disease, but does indicate an increased 
risk for allergic diseases [3]. For asthma and hay fever, 
respiratory sensitisers are of particular importance. 
In Western industrialised nations, the prevalence of 
allergic and, in particular, atopic diseases has increased 
significantly during the second half of the 20th century. 
The results of the ISAAC study (International Study of 
Asthma and Allergies in Childhood) and the repeated 
surveys of school-entry-age children in East and West 
Germany during the 1990s revealed further, yet fewer, 
pronounced increases in Germany [4-6]. The prevalence 
established by the baseline study of the German Health 
Interview and Examination Survey for Children and 
Adolescents (KiGGS, 2003-2006) can now be compared 
with those found in the second wave (2014-2017).
The article presents the lifetime and 12-month preva-
lences (‘ever’ and ‘during the past twelve months’) for 
bronchial asthma, hay fever and atopic dermatitis, as 
KiGGS Wave 2 
Second follow-up to the German Health 
Interview and Examination Survey for Children 
and Adolescents 
Data owner: Robert Koch Institute 
Aim: Providing reliable information on health 
status, health-related behaviour, living condi-
tions, protective and risk factors, and health 
care among children, adolescents and young 
adults living in Germany, with the possibility 
of trend and longitudinal analyses 
Study design: Combined cross-sectional and 
cohort study 
Cross-sectional study in KiGGS Wave 2
Age range: 0 -17 years
Population: Children and adolescents with 
permanent residence in Germany
Sampling: Samples from official residency 
registries - randomly selected children and  
adolescents from the 167 cities and municipal-
ities covered by the KiGGS baseline study
Sample size: 15,023 participants 
KiGGS cohort study in KiGGS Wave 2
Age range: 10 -31 years
Sampling: Re-invitation of everyone who took 
part in the KiGGS baseline study and who 
was willing to participate in a follow-up 
Sample size: 10,853 participants 
KiGGS survey waves
▶  KiGGS baseline study (2003-2006),  
examination and interview survey
▶  KiGGS Wave 1 (2009-2012),  
interview survey
▶  KiGGS Wave 2 (2014-2017),  
examination and interview survey
More information is available at 
www.kiggs-studie.de/english
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A serum sample was taken from 3- to 17-year-old 
children and adolescents that participated in KiGGS 
Wave 2 examinations, and analysed for specific IgE anti-
bodies. The PHADIA (now Thermo Fisher Scientific) 
IMMUNOCAP testing system was applied for quantita-
tive detection, using the UNICAP 1000 analyser. A value 
of ≥ 0,35 kUA/l was interpreted as a positive test result.
The results were stratified according to gender, 
age, region of residence (East/West Germany) and SES 
based on prevalences with 95% confidence intervals 
(95%-CI). To produce representative findings on regional 
structure and age (in years), gender, federal state (offi-
cial population statistics as of 31 December 2015), Ger-
man citizenship (as of 31 December 2014) as well as 
parental levels of education according to the Compara-
tive Analysis of Social Mobility in Industrial Nations 
(CASMIN) classification [13] (micro census 2013 [14]) a 
corresponding weighting factor was developed for anal-
yses. A separate weighting factor was created for labo-
ratory examinations. 
The basis for the description of trends between the 
KiGGS baseline study (data set version 23) and KiGGS 
Wave 2 were the age and gender standardised preva-
lences (as of 31 December 2015) at the point of data 
collection. New weighting factors were applied to the 
data from the KiGGS baseline study that were calculated 
in line with those applied to KiGGS Wave 2 data. 
All analyses were conducted with SAS 9.4 (SAS 
Institute, Cary, North Carolina, USA) based on the 
KiGGS Wave 2 data set (Version 7). To suitably account 
for the clustering of participants at sample points and 
the weighting in the calculation of confidence intervals 
KiGGS Wave 2 collected data on allergic diseases by 
using questionnaires which participants were asked to 
fill in (interview survey participants) or which were sur-
veyed in medical interviews (participants in both the 
interview and examination). Bronchial asthma, hay fever 
(allergic rhinitis or allergic conjunctivitis, atopic dermati-
tis (atopic eczema/endogenous eczema) and allergic 
contact dermatitis were surveyed through the questions 
“Has a physician ever diagnosed your child with the 
<disease X>?”, “Has the disease occurred during the 
past 12 months?” For children suffering from asthma, 
hay fever and/or atopic dermatitis parents and/or 
guardians were additionally asked; “Has your child taken 
medication for the <disease X> during the last 12 
months?” The data collected was used to calculate the 
lifetime and 12-month prevalence of allergic diseases.
The KiGGS baseline study surveyed data on allergic 
contact dermatitis for all participants by using self- 
administered questionnaires. The question was “Did 
your child ever develop an allergic contact dermatitis 
(for example a skin rash from nickel in a watch or jew-
ellery)?” Unlike in KiGGS Wave 2, answering ‘yes’ did 
not depend on having a medical diagnosis in the KiGGS 
baseline study.
Next to age and gender, the surveyed sociodemo-
graphic variables included family socioeconomic status 
(SES). In KiGGS Wave 2 the socioeconomic status was 
measured through an index based on the information 
parents provided on educational background, occupa-
tional status and income situation (equivalised dispos-
able income). SES allowed for a differentiation between 
low, medium and high SES groups [12].
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to the higher prevalence among boys in the age group 
7 to 10 years (5.7% vs. 4.1%) and 11 to 13 years (7.1% vs. 
5.7%; Figure 1). In absolute figures, nearly half a million 
children and adolescents in Germany currently suffer 
from asthma.
Hay fever
11.0% of children and adolescents in Germany have 
been diagnosed with hay fever at least once in their 
lives. Hay fever has also occurred over the last 12 
months among 8.8% of them, i.e. three quarters of 
these children and adolescents. Compared to girls, boys 
received a medical diagnosis of hay fever significantly 
more often (13.0% vs. 8.9%), and boys are also cur-
rently affected more frequently (10.4% vs. 7.2%).
The prevalence of hay fever increases continuously 
among girls and boys with age. The SES of parents 
has no significant impact on the prevalence of hay fever, 
either among girls or boys. Moreover, there are no 
significant differences between Eastern and Western 
Germany (Table 1 and Table 2). 
At the point of the KiGGS baseline study, the 
12-month prevalence of hay fever among 0- to 17-year-
olds was 8.1%. The current figures confirm that the 
prevalence of hay fever remains at a constantly high 
level. The characteristic differences according to 
gender and age that were observed originally with a 
higher prevalence among boys compared to girls and 
a clear increase of prevalence with age in both genders 
has also remained unchanged (Figure 2). In Germany, 
therefore more than one million children and adoles-
cents remain affected by hay fever.
and p-values, SAS survey procedures were applied in 
all analyses. A statistically significant difference between 
groups is assumed to have been demonstrated in cases 
where the corresponding 95% confidence intervals do 
not overlap and the p-value was lower than 0.01.
3.  Results
Bronchial asthma
The prevalence of children and adolescents from 0 to 17 
years ever receiving a medical diagnosis of asthma in 
Germany was 6.0%. 3.5% of children and adolescents 
in this age range also currently suffer from asthma, and 
that means it occurred during the last 12 months. Asth-
ma was detected far more frequently at least once in a 
lifetime among boys compared to girls (7.5% vs. 4.5%). 
Also boys currently suffer from asthma more often than 
girls (4.4% vs. 2.6%).
The prevalence of asthma increases among girls and 
boys up to about school age, although the increase is 
more marked for boys. The SES of parents too influences 
child asthma prevalences. The lowest prevalence of 
asthma is found among children and adolescents from 
families with high SES. A comparison of asthma preva-
lences between Eastern and Western Germany did not 
reveal any differences (Table 1 and Table 2). 
Overall, the 12-month prevalence of asthma has not 
changed significantly compared to the KiGGS baseline 
study (KiGGS Wave 2 3.5%, KiGGS baseline study 3.2%). 
Categorised by gender, prevalence has remained con-
stant for girls (2.6% vs. 2.7%) and slightly increased for 
boys (4.4% vs. 3.7%). Principally, the increase is owed 
The prevalence of hay fever, 
asthma and atopic dermatitis 
among children and  
adolescents has remained 
stable in Germany between 
the KiGGS baseline study 
(2003-2006) and KiGGS  
Wave 2 (2014-2017).
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Allerg. contact dermatitis 
(n=7,341 girls, 
n=7,254 boys)
% (95 % Cl) % (95 % Cl) % (95 % Cl) % (95 % Cl)
Total  
(girls and boys)
6.0 (5.5-6.6) 11.0 (10.3-11.8) 12.8 (12.1-13.6) 2.8 (2.5-3.2)
Girls 4.5 (3.9-5.2) 8.9 (8.0-9.8) 12.6 (11.6-13.7) 3.2 (2.7-3.8)
Boys 7.5 (6.6-8.4) 13.0 (11.9-14.2) 13.1 (12.0-14.2) 2.4 (2.0-2.9)
Region of residence
East 5.1 (4.2-6.1) 9.8 (8.8-11.0) 15.7 (14.4-17.2) 2.1 (1.7-2.8)
West 6.2 (5.6-7.0) 11.3 (10.4-12.2) 12.2 (11.3-13.1) 2.9 (2.5-3.4)
Socioeconomic status
Low 6.5 (5.1-8.3) 10.6 (8.9-12.6) 11.1 (9.3-13.3) 2.5 (1.7-3.7)
Medium 6.5 (5.8-7.4) 11.6 (10.7-12.6) 12.7 (11.8-13.7) 3.0 (2.5-3.6)
High 4.2 (3.6-4.8) 9.5 (8.5-10.6) 14.9 (13.5-16.4) 2.6 (2.0-3.3)
Age group  
(girls and boys)
0-2 Years 1.1 (0.5-2.5) 3.0 (1.9-4.7) 11.2 (9.2-13.5) 2.1 (1.2-3.7)
3-6 Years 3.6 (2.8-4.5) 4.5 (3.7-5.6) 12.4 (11.0-13.0) 1.9 (1.4-2.7)
7-10 Years 6.3 (5.1-7.6) 10.8 (9.4-12.3) 13.6 (12.1-15.1) 3.0 (2.4-3.9)
11-13 Years 8.4 (6.9-10.1) 15.6 (13.7-17.6) 12.7 (11.2-14.4) 3.4 (2.6-4.3)
14-17 Years 9.5 (8.3-10.8) 19.1 (17.3-21.0) 13.7 (12.5-15.0) 3.4 (2.7-4.2)
Girls
0-2 Years 0.9 (0.2-3.4) 3.3 (1.8-6.0) 10.1 (7.7-13.1) 1.4 (0.5-3.6)
3-6 Years 3.0 (2.0-4.5) 3.0 (2.1-4.1) 11.8 (9.9-14.0) 1.5 (0.8-2.6)
7-10 Years 4.4 (3.1-6.3) 7.8 (6.2-9.7) 13.6 (11.4-16.0) 4.2 (3.0-5.7)
11-13 Years 5.0 (3.8-6.7) 12.3 (10.1-15.0) 12.5 (10.6-14.8) 3.4 (2.4-4.7)
14-17 Years 7.8 (6.4-9.5) 16.6 (14.2-19.3) 14.0 (12.2-16.1) 4.8 (3.7-6.2)
Boys
0-2 Years 1.4 (0.5-3.6) 2.8 (1.4-5.5) 12.2 (9.0-16.3) 2.8 (1.3-5.6)
3-6 Years 4.1 (3.0-5.5) 6.1 (4.6-7.9) 12.9 (10.9-15.3) 2.4 (1.5-3.7)
7-10 Years 8.0 (6.5-9.9) 13.6 (11.4-16.0) 13.6 (11.6-15.8) 1.9 (1.3-2.8)
11-13 Years 11.4 (9.1-14.3) 18.6 (15.7-22.0) 12.9 (10.8-15.2) 3.3 (2.2-4.9)
14-17 Years 11.0 (9.3-13.0) 21.4 (18.8-24.2) 13.4 (11.5-15.6) 2.1 (1.4-3.0)
CI = Confidence interval
Table 1
Life time prevalences of allergic diseases 
according to gender, age, socioeconomic status 
and region of residence
Source: KiGGS Wave 2 (2014-2017)
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Allerg. contact dermatitis 





% (95 %-KI) % (95 %-KI) % (95 %-KI) % (95 %-KI) % (95 %-KI)
Total  
(girls and boys)
3.5 (3.1-4.0) 8.8 (8.2-9.5) 7.0 (6.4-7.6) 1.2 (1.0-1.5) 37.1 (34.6-39.7)
Girls 2.6 (2.2-3.2) 7.2 (6.4-8.1) 7.4  (6.6-8.3) 1.2 (1.0-1.5) 31.3 (28.3-34.3)
Boys 4.4 (3.7-5.2) 10.4 (9.4-11.4) 6.6  (5.8-7.4) 1.2 (0.9-1.6) 42.6 (39.0-46.4)
Region of residence
East 3.4 (2.8-4.2) 8.0 (7.2-8.9) 9.4 (8.5-10.3) 1.1 (0.8-1.4) 37.0 (33.2-40.9)
West 3.6 (3.1-4.1) 9.0 (8.3-9.8) 6.4  (5.8-7.1) 1.3 (1.0-1.5) 37.1 (34.2-40.2)
Socioeconomic status
Low 3.5 (2.5-4.9) 8.4 (6.8-10.2) 5.8  (4.4-7.5) 1.2 (0.7-2.1) 34.4 (28.8-40.5)
Medium 4.1 (3.5-4.7) 9.4 (8.6-10.2) 7.0  (3.3-7.8) 1.3 (1.0-1.6) 37.6 (34.3-41.0)
High 2.2 (1.7-2.7) 7.6 (6.7-8.6) 8.1  (7.1-9.2) 1.1 (0.7-1.6) 37.6 (33.1-42.4)
Age group  
(girls and boys)
0-2 Years 1.1 (0.5-2.5) 2.8 (1.7-4.4) 10.0 (8.0-12.3) 1.6 (0.8-2.8)  – 
3-6 Years 2.6 (2.0-3.4) 3.3 (2.6-4.3) 8.0  (6.9-9.2) 0.9 (0.6-1.4) 24.4 (19.6-29.9)
7-10 Years 4.3 (3.3-5.5) 8.7 (7.5-10.1) 7.0  (6.0-8.3) 1.2 (0.8-1.8) 34.4 (30.1-38.9)
11-13 Years 5.1 (4.0-6.5) 12.4 (10.6-14.4) 5.5  (4.6-6.5) 1.2 (0.8-1.8) 40.9 (36.4-45.6)
14-17 Years 4.2 (3.4-5.1) 15.3 (13.7-17.0) 5.1  (4.3-5.9) 1.3 (0.9-1.8) 47.7 (43.3-52.2)
Girls
0-2 Years 0.9 (0.2-3.4) 3.2 (1.7-5.9) 8.8 (6.5-11.8) 0.8 (0.3-2.0)  – 
3-6 Years 2.2 (1.5-3.3) 2.0 (1.3-3.0) 8.2 (6.6-10.2) 0.9 (0.5-1.7) 24.9 (18.9-31.9)
7-10 Years 2.8 (1.8-4.4) 6.0 (4.6-7.8) 8.3 (6.7-10.3) 1.4 (0.8-2.2) 26.2 (20.9-32.2)
11-13 Years 3.0 (2.0-4.5) 10.4 (8.3-13.0) 5.7  (4.4-7.4) 1.1 (0.6-2.0) 34.5 (28.6-41.0)
14-17 Years 3.7 (2.8-5.0) 13.3 (10.9-16.0) 6.0  (4.9-7.5) 1.8 (1.2-2.7) 39.0 (33.3-45.2)
Boys
0-2 Years 1.4 (0.5-3.6) 2.4 (1.1-5.1) 11.0 (8.0-15.1) 2.3 (1.1-4.8)  – 
3-6 Years 3.0 (2.1-4.1) 4.6 (3.4-6.2) 7.8  (6.4-9.3) 1.0 (0.5-1.8) 23.9 (17.8-31.4)
7-10 Years 5.7 (4.4-7.4) 11.3 (9.4-13.6) 5.8  (4.7-7.3) 1.1 (0.6-1.9) 42.3 (35.8-48.9)
11-13 Years 7.1 (5.2-9.5) 14.2 (11.5-17.4) 5.2  (4.1-6.7) 1.2 (0.6-2.4) 46.9 (40.0-54.0)
14-17 Years 4.6 (3.4-6.1) 17.2 (15.1-19.5) 4.2  (3.2-5.4) 0.8 (0.4-1.7) 55.7 (49.3-62.0)
CI = Confidence interval
 * Age range 3-17 years
Table 2
12-month prevalence of allergic diseases and 
sensitisation to inhalant allergens (SX1 test) 
according to gender, age, socioeconomic status 
and region of residence
Source: KiGGS Wave 2 (2014-2017)
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Trends in the 12-month prevalence of asthma 
between the KiGGS baseline study and 
KiGGS Wave 2 according to gender and age 
(KiGGS baseline study 
n=8,543 girls, n=8,849 boys; 
KiGGS Wave 2 
n=7,402 girls, n=7,317 boys)
Source: KiGGS baseline study (2003-2006), 
KiGGS Wave 2 (2014-2017)
Figure 2
Trends in the 12-month prevalence of hay fever 
between the KiGGS baseline study and 
KiGGS Wave 2 according to gender and age 
(KiGGS baseline study 
n=8,519 girls, n=8,829 boys; 
KiGGS Wave 2 
n=7,431 girls, n=7,367 boys)
Source: KiGGS baseline study (2003-2006), 
KiGGS Wave 2 (2014-2017)
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Lifetime prevalence and the number of current cases are 
higher in Eastern Germany compared to West Germany 
(Table 1 and Table 2). 
Compared to the KiGGS baseline study, no change in 
the number of current cases of atopic dermatitis has 
been observed (KiGGS Wave 2 7.0%, KiGGS baseline 
study 7.3%). Moreover, girls continue to be affected more 
often than boys (Figure 3). Expressed in absolute figures, 
around 900,000 children and adolescents in Germany 
suffer from atopic dermatitis.
At least one atopic disease
Grouping the three atopic diseases asthma, hay fever 
and atopic dermatitis together as ‘atopic diseases’, 
23.7% of children and adolescents in Germany have 
at some point in their lives evidently been diagnosed 
with an atopic disease. More than one in six children 
(16.1%) remain currently affected by one of these three 
diseases. This prevalence has not changed since the 
Atopic dermatitis
With a prevalence of 12.8% children and adolescents 
have ever been medically diagnosed with atopic dermati-
tis more frequently compared to hay fever and asthma. 
According to responses from parents, 7.0% of girls and 
boys also currently suffer from atopic dermatitis. Chil-
dren are most often diagnosed with atopic dermatitis at 
the age of 0 to 2 years. Lifetime prevalences are there-
fore stable over age groups. The levels of current atopic 
dermatitis, however, decrease with age and more signif-
icantly in boys than girls. 
The highest lifetime prevalences for atopic dermatitis 
are found among children and adolescents from 
families from the highest SES groups. Categorised 
according to gender and taking current cases into con-
sideration, the influence of SES is, however, not statisti-
cally significant. A clearer correlation with the prevalence 
of atopic dermatitis can be observed depending on 
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Trends in the 12-month prevalence of atopic 
 dermatitis between the KiGGS baseline study 
and KiGGS Wave 2 according to gender and age 
(KiGGS baseline study 
n=8,482 girls, n=8,787 boys; 
KiGGS Wave 2 
n=7,381 girls, n=7,341 boys)
Source: KiGGS baseline study (2003-2006), 
KiGGS Wave 2 (2014-2017)
16% of children and  
adolescents currently suffer 
from hay fever, asthma  
and/or atopic dermatitis.  
This corresponds to more 
than 2.1 million children and 
adolescents in Germany.
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Allergic sensitisation to inhalant allergens
37.1% of 3- to 17-year-olds are sensitised to SX1, a mix of 
the eight frequent inhalant allergens timothy grass, rye, 
birch, mugwort, cat and dog epithelial, house dust mites 
and the fungus cladosporium herbarum. The proportion 
of SX1 sensitised boys (42.6%) is higher than girls 
(31.3%). For both genders, the prevalence of SX1 sensi-
tisation increases continuously with age. More than half 
of all boys aged between 14 and 17 (55.7%) present a 
potential for allergy (Table 2).
The sensitisation to frequent inhalant allergens is not 
dependent on the SES of families of children and ado-
lescents. The region (East or West) also has no influence 
on SX1 sensitisation.
Compared to the KiGGS baseline study, the preva-
lence of SX1 sensitisation among children and adoles-
cents has increased slightly although not statistically 
significantly (KiGGS Wave 2 37.1%, KiGGS baseline study 
34.7%). The gender and age specific development of 
trends shown in Figure 4 reveals that SX1 sensitisation 
KiGGS baseline study (16.1% vs. 15.6%) and in abso-
lute figures affects 2.1 million children and adolescents 
in Germany.
Allergic contact dermatitis
Whereas in the KiGGS baseline study the data on aller-
gic contact dermatitis was self-reported, KiGGS Wave 2 
asked whether an allergic contact dermatitis had ever 
been medically diagnosed and whether the disease had 
appeared during the last 12 months. As expected the 
lifetime (2.8%) and 12-month (1.2%) prevalences are 
lower. For girls, the lifetime prevalences tend to be high-
er than for boys (3.2% vs. 2.4%; Table 1). These differ-
ences are statistically significantly higher for 7- to 10-year-
old and 14- to 17-year-old girls compared to boys of the 
same age. There are, however, no differences in the 
12-month prevalence of allergic contact dermatitis 
between gender and age groups (Table 2). In absolute 
figures 150,000 girls and boys are currently affected by 
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Trends in the prevalence of allergic 
sensitisation to the SX1 mix of allergens 
between the KiGGS baseline study and 
KiGGS Wave 2 according to gender and age 
(KiGGS baseline study 
n=6,348 girls, n=6,687 boys; 
KiGGS Wave 2 
n=1,499 girls, n=1,463 boys)
Source: KiGGS baseline study (2003-2006), 
KiGGS Wave 2 (2014-2017)
One in two adolescents in 
Germany is allergically  
sensitised.
Journal of Health Monitoring Allergic diseases in children and adolescents in Germany
Journal of Health Monitoring 2018 3(3)
FOCUS
12
Figures for allergic sensitisation based on measur-
ing IgE antibodies in the blood allows conclusions on 
the potential for allergies among children and adoles-
cents in Germany to be drawn. In particular sensitisa-
tion to inhalant allergens plays a role in the develop-
ment of hay fever and asthma. Although allergic 
sensitisation in itself is not a disease, it is nonetheless 
the basis for developing symptoms. The prevalence of 
sensitisation to a mix of eight frequent inhalant aller-
gens shows potential for allergies in one in two ado-
lescents. Similar to the development of disease preva-
lence, the prevalence of SX1 sensitisation over the 
course of the last ten years has remained stable at a 
high level. Unlike in girls, the trend for boys has seen 
a slight increase.
The degree to which individuals maintain allergic 
sensitisations over their life course, newly develop or 
lose sensitisations is an important research question 
that can be analysed based on the KiGGS cohort data. 
Initial results indicate that new sensitisations to SX1 
allergens occur significantly more often than remissions 
and that once acquired, sensitisations usually remain 
[15]. As sensitisations do not seem to disappear to any 
significant degree with age, providing healthcare to peo-
ple affected by allergies will most likely become an 
increasingly important field of action for the health care 
system of years and decades to come, even if preva-
lences of those of similar age stop increasing over time.
The prevalences estimated currently for Germany 
among children and adolescents are reflected in the 
results of regional examinations such as the school entry 
examinations in Bavaria in 2012/2013 [16]. Comparisons 
has increased most strongly among 14- to-17-year-old 
boys (55.7% vs. 47.7%; p=0.03).
4.  Discussion
Following the well-known trend of a clear increase dur-
ing the second half of the 20th century, allergic diseases 
have become prominent diseases relevant to public 
health. Population measures as an adequate response 
that strives to increase knowledge about allergic diseases, 
promote prevention, diagnosis and therapy requires a 
continuous flow of generated key epidemiologic figures 
on the prevalence of allergies. Since the turn of the cen-
tury, population-based health monitoring at the Robert 
Koch Institute has decisively contributed to generating 
data on allergic diseases in Germany.
Most recent data from KiGGS Wave 2 on the current 
prevalence (12-month prevalence) of the most common 
allergic diseases such as hay fever (8.8%), atopic der-
matitis (7.0%) and bronchial asthma (3.5%) among chil-
dren and adolescents reveal that no significant changes 
have occurred relative to the KiGGS baseline study, which 
indicates a stabilisation of allergy prevalence at a high 
level. To a certain degree, gender and age-specific devel-
opments are however noteworthy, for example the greater 
prevalence of asthma among 7- to 13-year-old boys com-
pared to the prevalence found among boys of the same 
age around ten years previously. Current results by no 
means indicate a change of trend. Today around one in 
six children (16.1%) are affected by at least one of these 
three diseases. In absolute figures, this translates into 
over 2.1 million children and adolescents in Germany. 
The high number of people 
affected throws up a  
great deal of future challenges 
to the health system.
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A principal strength of the available cross-sectional 
analyses is that the observed results can be generalised 
to reflect the German population from sampling, imple-
mentation and weighting. As in all surveys, bias due to 
selective non-participation is possible. As far as trend 
analyses are concerned, possible effects from changing 
the survey format from the KiGGS baseline study to 
KiGGS Wave 2 have to be considered. Whereas in the 
KiGGS baseline study, a personal interview with a physi-
cian took place during the examination period, partici-
pants in KiGGS Wave 2 were either personally inter-
viewed or received a disease questionnaire by post to fill 
in. The analyses of responses of both sample groups 
(interview sample/interview and examination sample) 
revealed no significant deviations in the prevalence of 
allergic diseases meaning that a joint analysis of both 
groups became possible. 
Current developments of the spread of allergic 
diseases among children and adolescents in Germany 
clearly show the continuously high number of cases. For 
patients, their families and the interested public, the 
Helmholtz Zentrum München has been developing its 
allergy information service in cooperation with the Fed-
eral Ministry of Health since 2017 to provide, via the 
internet, readily understandable information that is up 
to date and scientifically secured from the fields of allergy 
research and allergology [26]. From an academic per-
spective, the current guideline on specific immunother-
apy only deals with the existing causal therapy for aller-
gies. On its website, the German Society for Allergology 
and Clinical Immunology (DGAKI) updates the guideline 
every six months with updated information on specific 
of prevalences with studies from other European and 
non-European countries are only possible to a very lim-
ited degree due to the use of different survey instruments 
in different study populations based on diverging case 
definitions as well as different examination periods. The 
dimension of prevalences in Germany, however, does 
correlate quite well with those reported by other Euro-
pean countries [17-24]. To gain meaningful and repre-
sentative results on prevalence and trends of allergic 
diseases in Germany, regular surveying in the context of 
health monitoring that is based on a comparable method-
ology will be required. Going beyond disease prevalence, 
future monitoring studies will survey the prevalence of 
symptoms. Not only will this increase the disease spec-
ificity of data, it will also lead to a better comparability 
with other symptoms-related surveys such as, for exam-
ple, the ISAAC study, the largest international study so 
far on the spread of asthma and allergies among 
children and adolescents. A regular comparison of reli-
able data on the health, health behaviour and care as 
well as socioeconomic variables at the European level, 
the European Health Interview Survey (EHIS) has been 
developed. EHIS data is collected based on uniform 
standards and applies and further develops harmonised 
surveying tools across various countries [25]. 
In addition to increasing disease specificity by improv-
ing questions, it is currently being considered whether 
the format in which data is regularly collected in KiGGS 
studies, which is based on a standardised collection of 
data on diseases through reporting, should or could be 
validated by medical diagnoses through corresponding 
data sources for example billing data.
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